Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Farrukh Awan, MBBS
Advertisement
Articles by Farrukh Awan, MBBS
Farrukh T. Awan, MBBS, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia who were previously treated with a B-cell receptor pathway signaling inhibitor.
Advertisement
Latest Updated Articles
Dr. Farrukh Awan on Clinical Activity of Entospletinib in Patients with CLLPublished: December 7th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
